In NAFLD rodent models, 12‐week supplementation with hesperidin was related to a meaningful reduction in some inflammatory molecules such as TNF‐α, IL‐6, and IL‐1β. This evidence concerns the gene IL6 and metabolic dysfunction-associated steatotic liver disease.